Your browser is no longer supported. Please, upgrade your browser.
Ascendis Pharma A/S
Index- P/E- EPS (ttm)-9.56 Insider Own0.03% Shs Outstand53.76M Perf Week2.19%
Market Cap6.29B Forward P/E- EPS next Y-8.00 Insider Trans0.00% Shs Float43.77M Perf Month-10.16%
Income-497.30M PEG- EPS next Q-2.20 Inst Own- Short Float6.12% Perf Quarter-18.47%
Sales6.50M P/S968.07 EPS this Y-76.60% Inst Trans0.53% Short Ratio13.04 Perf Half Y-21.29%
Book/sh17.75 P/B6.66 EPS next Y3.40% ROA-47.10% Target Price191.44 Perf Year-15.54%
Cash/sh14.84 P/C7.96 EPS next 5Y24.00% ROE-54.50% 52W Range109.36 - 183.98 Perf YTD-29.13%
Dividend- P/FCF- EPS past 5Y-43.00% ROI-35.50% 52W High-35.76% Beta0.72
Dividend %- Quick Ratio9.40 Sales past 5Y-3.10% Gross Margin- 52W Low8.07% ATR4.31
Employees482 Current Ratio9.40 Sales Q/Q-68.20% Oper. Margin- RSI (14)39.22 Volatility3.92% 3.60%
OptionableYes Debt/Eq0.12 EPS Q/Q11.50% Profit Margin- Rel Volume1.27 Prev Close116.90
ShortableYes LT Debt/Eq0.11 EarningsMay 27 AMC Payout- Avg Volume205.38K Price118.19
Recom1.60 SMA20-3.51% SMA50-8.98% SMA200-19.64% Volume262,346 Change1.10%
Mar-30-21Downgrade Oppenheimer Outperform → Perform
Mar-11-21Resumed Stifel Buy $190
Dec-17-20Initiated Berenberg Buy $216
Sep-14-20Resumed JP Morgan Overweight $160
Mar-20-20Initiated Oppenheimer Outperform $199
Oct-11-19Initiated Morgan Stanley Overweight $128
Mar-25-19Initiated Evercore ISI Outperform
Jan-24-19Upgrade Leerink Partners Mkt Perform → Outperform
Jan-24-19Initiated Cantor Fitzgerald Overweight $102
Jun-26-18Initiated Stifel Buy $85
Apr-02-18Reiterated Leerink Partners Mkt Perform $37 → $64
May-11-17Initiated JP Morgan Overweight $36
Mar-09-17Downgrade Leerink Partners Outperform → Mkt Perform
Feb-09-17Initiated Credit Suisse Outperform $28
Sep-26-16Initiated Wedbush Outperform $34
Jul-26-21 11:01AM  
Jul-12-21 01:10PM  
Jul-06-21 08:00AM  
Jun-14-21 10:41AM  
Jun-11-21 05:57PM  
Jun-03-21 01:59PM  
May-28-21 01:00PM  
May-27-21 04:01PM  
May-17-21 04:05PM  
May-14-21 01:38AM  
May-12-21 04:28PM  
May-11-21 08:17AM  
May-10-21 05:17PM  
May-06-21 04:05PM  
May-04-21 04:05PM  
Apr-21-21 04:05PM  
Apr-19-21 03:19PM  
Apr-07-21 09:45PM  
Mar-30-21 07:05AM  
Mar-23-21 07:05AM  
Mar-15-21 07:05AM  
Mar-11-21 05:30AM  
Mar-10-21 04:01PM  
Mar-09-21 10:16AM  
Mar-04-21 04:05PM  
Feb-26-21 07:05AM  
Feb-18-21 04:05PM  
Jan-14-21 08:29AM  
Jan-13-21 11:02AM  
Jan-10-21 07:04PM  
Jan-08-21 10:06PM  
Jan-04-21 07:05AM  
Dec-30-20 04:05PM  
Dec-14-20 04:05PM  
Nov-25-20 07:05AM  
Nov-15-20 07:20AM  
Nov-11-20 05:30PM  
Nov-10-20 08:40AM  
Nov-04-20 10:12AM  
Nov-03-20 07:05AM  
Nov-02-20 04:05PM  
Oct-23-20 08:05AM  
Oct-21-20 05:51PM  
Oct-08-20 06:40PM  
Sep-29-20 11:04AM  
Sep-28-20 07:00PM  
Sep-23-20 04:05PM  
Sep-15-20 05:45PM  
Sep-11-20 07:05AM  
Sep-10-20 07:05AM  
Sep-08-20 04:44PM  
Sep-04-20 08:30AM  
Sep-02-20 04:05PM  
Aug-27-20 10:00PM  
Aug-21-20 09:48AM  
Aug-13-20 04:01PM  
Aug-12-20 07:05AM  
Aug-04-20 08:30AM  
Jul-24-20 09:47AM  
Jul-10-20 08:49PM  
Jul-07-20 10:11PM  
Jul-06-20 12:58PM  
Jun-29-20 11:44AM  
Jun-26-20 08:29AM  
Jun-22-20 08:30AM  
Jun-10-20 12:27PM  
Jun-08-20 08:15AM  
Jun-03-20 03:46PM  
May-29-20 09:28PM  
May-22-20 06:14AM  
May-19-20 04:01PM  
May-11-20 08:30AM  
May-08-20 11:46AM  
May-07-20 04:01PM  
Apr-21-20 06:01AM  
Apr-19-20 04:00PM  
Apr-16-20 09:40PM  
Apr-15-20 04:58PM  
Apr-01-20 04:01PM  
Mar-25-20 04:01PM  
Mar-22-20 08:25PM  
Mar-21-20 08:49AM  
Mar-17-20 12:00PM  
Feb-12-20 04:01PM  
Ascendis Pharma A/S, a biopharmaceutical company, develops therapeutics for unmet medical needs. The company develops TransCon growth hormone, which completed Phase III clinical trials for growth hormone deficiency. It also develops TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for achondroplasia. In addition, the company develops preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.